WO2010040262A1 - 分离动物胚胎间质性干细胞并提取其分泌物的方法 - Google Patents

分离动物胚胎间质性干细胞并提取其分泌物的方法 Download PDF

Info

Publication number
WO2010040262A1
WO2010040262A1 PCT/CN2008/072648 CN2008072648W WO2010040262A1 WO 2010040262 A1 WO2010040262 A1 WO 2010040262A1 CN 2008072648 W CN2008072648 W CN 2008072648W WO 2010040262 A1 WO2010040262 A1 WO 2010040262A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
cells
mesenchymal stem
interstitial
cell
Prior art date
Application number
PCT/CN2008/072648
Other languages
English (en)
French (fr)
Inventor
连祺周
夏建川
Original Assignee
深圳市嘉天源生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市嘉天源生物科技有限公司 filed Critical 深圳市嘉天源生物科技有限公司
Priority to PCT/CN2008/072648 priority Critical patent/WO2010040262A1/zh
Priority to CA2740092A priority patent/CA2740092A1/en
Priority to JP2010532419A priority patent/JP2010538681A/ja
Priority to AU2009301517A priority patent/AU2009301517A1/en
Priority to CN200980000501A priority patent/CN101802177A/zh
Priority to PCT/CN2009/074031 priority patent/WO2010040302A1/zh
Priority to KR1020107006511A priority patent/KR20100065338A/ko
Priority to EP09818766A priority patent/EP2368974A1/en
Priority to US12/678,745 priority patent/US20110217385A1/en
Publication of WO2010040262A1 publication Critical patent/WO2010040262A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0605Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0668Mesenchymal stem cells from other natural sources

Definitions

  • the present invention relates to the field of cell biology, and more particularly to a method of isolating animal embryonic interstitial stem cells and extracting their secretions.
  • MSC tissue stem cells with multipotential and self-renewal ability that can differentiate into a variety of tissue cells: osteogenesis, cartilage, fat, nerve cells, etc. It was first isolated from the bone marrow. In recent years, interstitial cells with characteristics of stem/progenitor cells have been isolated from bone marrow, peripheral blood, dense bone, cartilage, muscle and other tissues. The common feature of these tissues is that they are composed of mesenchyme and blood vessels derived from extraembryonic mesoderm. Interstitial stem cells are easily isolated and purified from bone marrow for efficient in vitro expansion, which has the effect of improving the bone marrow environment and promoting hematopoietic reconstitution.
  • interstitial stem cells do not express or only negligible levels of MHC class II molecules, and interstitial stem cells from unrelated donors do not cause allogeneic lymphocyte responses and down-regulate allogeneic immune responses. Due to the above characteristics, MSC has rapidly become an ideal engineering cell for cell therapy, gene therapy, etc. since its discovery, and an important seed cell for tissue engineering, especially bone or cartilage tissue damage repair.
  • the interstitial stem cells reported so far are mainly derived from bone marrow, and are obtained by density gradient separation.
  • the donor needs to undergo a painful operation, and there is a high probability of infection during and after taking the material.
  • the content of human bone marrow interstitial stem cells is extremely rare, every 105 ⁇ 106 single cores
  • There is only one interstitial stem cell in the cell and with the increase of age, or the infection, tumor and other diseases, the number of bone marrow interstitial stem cells and proliferation and differentiation ability are significantly reduced, making it especially in research and application. There are significant limitations in clinical applications.
  • Figure 1 shows a conventional method for separating interstitial stem cells in the prior art, comprising the following steps: (1) The placenta is bled immediately after delivery from the uterus to obtain a sample; (2) ⁇ is continuously perfused, Or use collagenase digestion to obtain a single cell suspension; (3) Obtaining interstitial stem cells by single-cell suspension by density gradient centrifugation or immunomagnetic separation.
  • the prior art has a low yield and cannot quickly get a large number of rooms.
  • Qualitative stem cells, and the purity is low; in addition, the degree of damage to the cells during the treatment process is serious, and it is difficult to ensure the quality of the interstitial stem cells; in addition, due to the low yield, it is difficult to extract secretions with good application prospects. .
  • One of the objects of the present invention is to provide a method for isolating animal embryonic interstitial stem cells and extracting secretion thereof, which aims to solve the prior art that the yield rate, purity is low, and it is difficult to ensure cell quality. The problem.
  • the method of isolating animal embryonic interstitial stem cells comprises the steps of:
  • the step A comprises: A1. Heparin-containing physiological saline (50 units of heparin/ml) in the inner tissue block of the placenta and/or the blood in the umbilical cord
  • the enzyme digestion solution in the step B comprises a mixture of trypsin-EDTA (0.05%) and type IV collagenase, and is mixed in a ratio of 1:1.
  • the digesting step in the step B comprises: adding the enzyme digestive solution to a centrifuge tube, and digesting 1.5-2 sputum in a 37 ° C constant temperature water bath shaker.
  • the step of preparing the single cell suspension in the step B comprises: adding 3-5 times of physiological saline to the solution after the digestion is completed, shaking uniformly, and sucking the ⁇ cell sieve with an electric pipetting gun. The mesh is thus made into a single cell suspension.
  • the step C comprises: C1.
  • the single cell suspension is centrifuged at 1600 rpm for 10 minutes, and the supernatant is removed;
  • the adherent purification treatment in the step D comprises: aspirating the unattached cells with a pipette, washing with physiological saline, and replacing with the new interstitial stem cell type A culture medium to continue the culture,
  • the adherent cells were expanded to 70% of the flask volume and digested with trypsin-EDTA (0.05%) to obtain a single cell suspension.
  • the magnetic bead sorting in the step D comprises: using the immunomagnetic beads separation method, screening the single cell from the CD271 and CD73 double positive cell population, that is, the separation from the placenta Qualitative stem cells.
  • the method further comprises: E. adding and passing the obtained mesenchymal stem cells.
  • the method further comprises: F. extracting the secretion liquid of the interstitial stem cells.
  • the step F comprises: F1. digesting the interstitial stem cells with the enzyme digestive solution; F2. adding the medium to the collected cells for inoculation culture, and adding the interstitial stem cell type B The culture medium promotes the cells to produce more secretion factors; F3. Centrifugally filter the collected culture solution to obtain a secretion.
  • the enzyme-based digestive juice in the step F1 means trypsin-EDTA (0.05%).
  • the method for extracting secretions of interstitial stem cells comprises the following steps: [24] ⁇ '. digesting interstitial stem cells with an enzyme digestive solution;
  • the step A' comprises: A' l. digesting the interstitial stem cells with trypsin-EDTA (0.05%); A, 2. when the interstitial stem cells are rounded off ⁇ The digestion was terminated with 1640 medium containing bovine serum.
  • the step of adding the medium to the inoculation culture in the step B' comprises: adding the interstitial stem cell culture medium to the collected cells, shaking and adjusting to 5-8 ⁇ 10 4 cells/ml of cells. Density; The adjusted solution was inoculated into a plurality of culture flasks, and cultured in an incubator at 5% CO 2 , 37 ° C, and saturated humidity.
  • the step of adding the interstitial stem cell type B culture solution to the cells to produce more secretory factors in the step B' comprises: amplifying the cell layer when the cell layer in the culture bottle is expanded to 80% ⁇ It was washed with phosphate buffer; interstitial stem cell type B medium was added to stimulate interstitial stem cells to produce more secretory factors.
  • the step C comprises: collecting the culture solution, collecting the supernatant after centrifugation at 2000 rpm for 8 minutes; filtering with a 0.22 u filter to obtain a secretion.
  • the method further comprises: D′. concentrating the secretion.
  • the step D' comprises: D' l. adding the harvesting liquid to the ultrafiltration cup to the working volume to complete the assembly; D'2. filtering with nitrogen, and collecting the filtered concentrated liquid.
  • the 1:1 mixed enzyme digestion solution comprises mixed trypsin-EDTA (0.05%) and type IV collagenase as enzyme digestive juices.
  • the interstitial stem cells screened by adherent purification and immunomagnetic beads can improve the purity;
  • the interstitial stem cell culture The addition of type B stem cell culture solution during the process can stimulate interstitial stem cells to produce more secretory factors. Therefore, the exudates extracted from interstitial stem cells contain more cell secreting factors.
  • FIG. 1 is a flow chart of a method for separating interstitial stem cells in the prior art
  • FIG. 2 is a flow chart of a method for isolating animal embryonic interstitial stem cells in a fourth embodiment of the present invention.
  • Figure 3 is a flow chart showing a method for isolating animal embryonic interstitial stem cells in a fourth embodiment of the present invention.
  • Figure 4 is a schematic diagram showing the early isolation and purification of mesenchymal stem cells in a fourth embodiment of the present invention.
  • Figure 5 is a schematic diagram of the interstitial stem cells that are proliferating in the fourth embodiment of the present invention.
  • Figure 6 is a schematic illustration of a large number of expanded interstitial stem cells in a fourth embodiment of the present invention.
  • Figure 7 is a schematic diagram showing the expression and identification of surface proteins of intermediate stem cells in the fourth embodiment of the present invention.
  • Figure 8 is a schematic diagram showing the differentiation of placental mesenchymal stem cells into fat, cartilage and osteoblasts by a cytochemical method according to a fourth embodiment of the present invention.
  • Figure 9 is a flow chart showing a method for extracting secretions of interstitial stem cells in a fourth embodiment of the present invention.
  • Figure 10 is a flow chart showing a method of extracting secretions of interstitial stem cells in one embodiment of the present invention.
  • Figure 11 is a schematic diagram showing the identification of secretory factors of mesenchymal stem cells in one embodiment of the present invention.
  • Figure 12 is a diagram showing a large amount of cell growth factor population and collagen molecule group in the secretion of interstitial stem cells detected in an embodiment of the present invention
  • Figure 13 is a schematic illustration of the role of an interstitial stem cell exudate in epidermal repair in accordance with one embodiment of the present invention.
  • Figure 14 is a schematic illustration of the use of an intermediate stem cell exudate in regenerative medicine in accordance with one embodiment of the present invention.
  • the 1:1 mixed enzyme digestion solution comprises mixed trypsin-EDTA (0.05%) and type IV collagenase as enzyme digests, which can obtain the most Single cells, the same level of cell damage is minimized; in addition, mesenchymal stem cells are screened by adherent purification and immunomagnetic beads separation to improve purity; in addition, type B is added during the process of mesenchymal stem cell culture Stem cell culture fluid can stimulate interstitial stem cells to produce more secretory factors. Therefore, extracting exudates from interstitial stem cells contains more cell secreting factors.
  • step S201 shows a method flow for separating animal embryonic interstitial stem cells in one embodiment of the present invention, comprising the steps of: in step S201, centrifuging a sample based on animal placenta and/or umbilical cord sampling; In step S202, the sample is digested with the enzyme digestive solution, and a single cell suspension is prepared; in step S203, the interstitial stem cell type A culture solution is added to the separated single cells, and the cells are inoculated and cultured; In step S204, the cells are subjected to adherent purification treatment, and interstitial stem cells are obtained by magnetic bead sorting.
  • Figure 3 is a flow chart showing the method of isolating animal embryonic interstitial stem cells in one embodiment of the present invention, comprising the steps of: in step S301, centrifuging the sample based on animal placenta and/or umbilical cord sampling.
  • the specific process and step S201 are the same; in step S302, the sample is digested with an enzyme digestive solution, and a single cell suspension is prepared.
  • the specific process and step S202 are the same; in step S303, the isolated single cells are obtained by the single cell suspension, and the interstitial stem cell type A culture solution is added to the isolated single cells, and the cells are inoculated and cultured.
  • step S203 The specific process and step S203 are the same; in step S304, the cells are subjected to adherent purification treatment, and the interstitial stem cells are obtained by magnetic bead sorting.
  • step S204 the specific process and step S204 are performed; in step S305, the obtained mesenchymal stem cells are subjected to value addition and passage. This step is equivalent to an extension made on the basis of Figure 1.
  • the specific implementation process of the foregoing steps S201 and S301 is: [53] (1)
  • the blood in the inner tissue block of the animal placenta and/or the blood in the umbilical cord is washed with heparin-containing physiological saline, and the sample is cut into pieces.
  • the animal referred to in the present invention is a broad concept including higher animals and lower animals, and thus the placenta used may include a human placenta and a placenta of animals such as cattle and horses, and the scope of protection of the present invention is not Limited to animal species.
  • the treatment of the placenta is: removing the fresh placenta with scissors to remove the outer membrane, taking the inner dark red tissue block, preferably taking the tissue of the dense blood vessel, where the blood vessels are interwoven Root of the tree, wash the blood in the tissue with normal saline (plus heparin, 500 ml of saline plus 2 heparin, 12500 IU / support, final concentration: 50 units of heparin / ml saline), wash it with heparin-free saline Then use scissors to cut the tissue pieces (the more broken the better).
  • the umbilical cord is treated by cutting the umbilical cord into about 2 cm sections, washing the blood with heparin-containing saline, cutting it longitudinally, washing the internal blood, washing it once with heparin-free saline, and using the scissors to take the umbilical cord. Cut it.
  • the invention is not limited to the above.
  • the collected sample is placed in a 50 ml centrifuge tube containing physiological saline, centrifuged at 12 rpm, 10 min.
  • step S202 and step S302 are:
  • a 1: 1 mixture of pancreatin-EDTA (0.05%) and type IV collagenase is used as an enzyme digestive solution to digest the placenta, and the digestive tract is 1.5-2 hours.
  • the ratio ratio scheme and digestive enthalpy (1.5 - 2h) used in the present invention can achieve the best effect;
  • the protocol and digestive tract (1.5 - 2h) can minimize the degree of digestive damage of the enzyme, and the most single cells can be obtained at the same time. Therefore, the two enzymes are configured and digested during the digestion process. Separation of mesenchymal stem cells from human placenta is critical.
  • the specific implementation process of the above steps S203 and S303 is as follows: (1) The single cell suspension is centrifuged at 1600 rpm for 10 minutes to remove the supernatant. (2) Add interstitial stem cell type A medium, shake and adjust to a cell density of 5-8x10 4 cells/ml. (3) Inoculate the adjusted solution in a 6-well plate , Incubate in an incubator at 5% C0 2 , 37 ° C, and saturated humidity.
  • step S204 and step S304 are:
  • Adherent purification treatment including:
  • a single cell obtained by ordinary centrifugation (1600 r/min) of a single cell suspension obtained by digestion with 1:1 mixed trypsin-EDTA (0.05%), in this single cell population Cells with many different biological properties are also mixed with dead cells. Then, the cells cultured with the cultured mesenchymal stem cells are screened, and most of the cells that can survive and adhere to the growth are mesenchymal stem cells, and a large number of non-interstitial stem cells can be removed by adherent purification.
  • CD271 and CD73 double positive cell populations i.e., interstitial stem cells isolated from placenta, were screened from the single cells. Magnetic bead sorting can obtain a large number of live, high-purity interstitial stem cells in the shortest space.
  • the specific implementation process of the above step S305 is: (1) Aspirating the medium in the bottle with a pipette. (2) Add a small amount of phosphate buffer (phosphate buffered
  • FIG. 4 shows an interstitial stem cell isolated and purified in an early embodiment of the present invention
  • FIG. 5 is an interstitial stem cell which is proliferating in one embodiment of the present invention
  • FIG. 6 is an embodiment of the present invention.
  • a large number of expanded interstitial stem cells In the example A large number of expanded interstitial stem cells.
  • Figure 7 is a schematic representation of the identification of surface protein expression of intermediate stem cells in one of the embodiments of the present invention.
  • the method for detecting placental interstitial stem cells by flow cytometry indicates the expression of cytokines, and it can be seen that the isolated cultured placental mesenchymal stem cells express CD9, CD29, CD 105s CD166 surface protein, and do not express CD34.
  • CD13, CD14, CD45 surface proteins the cell's biological characteristics are stable, and the cell homogeneity after amplification for one and two generations is 95% and 98%, respectively.
  • the hollow light curve is a negative control representing a cytokine expression
  • the solid black color pattern indicates the level of expression of the corresponding cytokine in the cell population. If the solid black color pattern is farther away from the hollow light curve, the positive rate of this cytokine is higher.
  • Placental mesenchymal stem cells can still have multi-directional differentiation potential after continuous subculture and cryopreservation, and maintain normal nuclear telomerase activity, but not easy to spontaneously differentiate.
  • PDMSC can differentiate under specific induction conditions in vitro. For bone, cartilage, fat, tendon
  • Figure A shows that after the addition of the adipogenic inducer, the placental mesenchymal stem cells differentiate into adipocytes and the oil red staining is positive, and the orange-red lipid droplets are visible in the pulp.
  • Panel B shows that after the addition of the osteogenic inducer, the placental stem cells differentiate into osteoblasts, and Von Kossa performs osteoblast identification. Von
  • Panel C shows the induction of cells by the addition of a cartilage inducer, and the expression of proteoglycans was shown by Alcian blue staining.
  • Figure D Immunohistochemical method showed that the expression of collagen-specific chondrocytes-chnotage cells was expressed after induction of differentiation.
  • PDMSC placental mesenchymal stem cells
  • hESC human embryonic stem cells
  • mESC mouse embryonic stem cells
  • PDMSCs Placental mesenchymal stem cells
  • hESC human embryonic stem cells
  • mESC mouse embryonic stem cells
  • MEF mouse embryonic fibroblasts
  • hES C human embryonic stem cells
  • mESQ mouse embryonic stem cells
  • MEF mouse embryonic fibroblasts
  • Extraction of a large number of mouse embryonic fibroblasts requires the killing of many mice.
  • Use of healthy human-derived placental mesenchymal stem cells (PDMSC) as embryonic stem cells The nourishing layer has unique advantages: 1. Avoid sacrificing a lot of small Rats, taken from discarded placental tissue derived from healthy humans; 2. Avoiding the risk of animal-derived contamination; 3. Using human placental mesenchymal stem cells (PDMSCs) as a trophoblast for human embryonic stem cells is more beneficial for culturing human embryonic stem cells .
  • PDMSC mouse embryonic fibroblasts
  • step S901 the interstitial stem cells are digested with an enzyme digestive solution.
  • step S902 medium is added to the collected cells for inoculation culture, and interstitial stem cell type B medium is added to promote the cells to produce more secretory factors.
  • step S903 the collected culture solution is centrifuged to obtain a secretion.
  • FIG. 10 is a flow diagram of a method of extracting secretions of interstitial stem cells in one of the embodiments of the present invention.
  • the interstitial stem cells are digested with an enzyme-based digestive juice.
  • the specific implementation process is the same as step S901 in FIG.
  • step S1002 medium is added to the isolated single cells for inoculation culture, and interstitial stem cell type B medium is added to promote the production of a large amount of secreted factors by the cells.
  • the specific implementation process is the same as step S902 in FIG.
  • step S1003 the collected culture solution is centrifuged to obtain a secretion.
  • the specific implementation process is the same as step S903 in FIG.
  • the secretion is concentrated.
  • step S901 and step S1001 includes:
  • the specific procedure of the above steps is as follows: After the cells are extensively expanded, the cells are grown to about 80% in a 175 cm2 culture bottle, and trypsin-EDTA (0.05%) is added.
  • step S902 and step S1002 includes:
  • the specific process of the above steps is: adding interstitial stem cell culture medium to the collected cells, shaking and adjusting to a cell density of 5-8 ⁇ 10 4 cells/ml; The solution was inoculated into a culture flask and cultured in an incubator at 5% CO 2 , 37 ° C, and saturated humidity. [86] (2) Adding interstitial stem cell type B culture medium to promote the production of more secretory factors.
  • the specific process of the above steps is: when the cell layer in the culture flask is expanded to 80
  • % ⁇ aspirate the culture solution and wash it with phosphate buffer; add interstitial stem cell type B medium to stimulate interstitial stem cells to produce more secretory factors.
  • step S903 and step S1003 includes:
  • the specific procedure of the above steps is: collecting the culture solution after 3 days of culture. Pass 200
  • the harvested liquid was centrifuged at 0 G, 8 min, cell debris was removed, and the supernatant was collected.
  • the specific process of the above steps is: filtration with a 0.22u filter, storage of the filter at -20 ° C for 2 days, and then placed at -80 ° C Save for a long time.
  • step S1004 includes:
  • An ultrafiltration membrane is required before performing the steps described below. The process is: first rinse the ultrafiltration membrane with 75% alcohol and soak it for 10 minutes; clamp the edge of the membrane with tweezers, rinse it with water for 3 times, and then soak it in a clean container of water for injection overnight.
  • the specific process of the above steps is as follows: the membrane, the cup, the stirring system are installed according to the ultrafilter cup instruction, the harvesting liquid is added to the working volume, and the lid and the protective cover are attached.
  • the specific process of the above steps is: after the nitrogen gas is connected to the filtration, it should be noted that the filter should be slowly pressurized after the filter is started, and then the magnetic stirrer is pressed after the pressure; The medium nitrogen pressure should not exceed 55 PSI; the pressure should be slowly reduced after the end of filtration. Finally, when the harvested liquid in the ultrafiltration cup is concentrated to 25 times, the concentration is stopped, and the concentrate is collected in a clean bench and stored in a -80 ° C refrigerator for later use.
  • FIG 11 is a schematic illustration of the secretory factors identifying interstitial stem cells in one of the embodiments of the present invention.
  • the placental mesenchymal stem cell secretory factor product contains a large amount of protein molecules.
  • placental mesenchymal stem cells secrete many growth factors, proteins, active peptides and other substances that promote cell growth and tissue regeneration.
  • the cytokine secreted by placental interstitial stem cells by silver staining is significantly different from the control group, and the placental interstitial stem cell secretion contains a large amount of special Some protein molecules.
  • Figure 12 is a view showing a large amount of a cell growth factor group and a collagen molecule group in the secretion of mesenchymal stem cells detected in one of the embodiments of the present invention.
  • the placental stem cell secretory factor proteome was evaluated using a cytokine antibody array. A large number of placental mesenchymal stem cells have been found to secrete unique gene products.
  • These gene products contain a large number of growth factor groups related to cell growth and metabolism, such as: B DNF, EGF, FGF, FGF17, FGF4, FGF6, FGF7, FGF9 , GDNF, HGF, IGFB p, PDGFBs PIGF, TGFB1, TGFb2, TNFRSF11B, VEGF, IGF1 and LEP; and a large number of collagen molecules, such as: C0L11A1, C0L12A1, C0L16A1, C0L1A, C0L3A1, C0L4A1, COL5A and COL6A, etc. .
  • These protein molecular groups play an important role in promoting cell growth and metabolism.
  • FIG. 13 is a schematic illustration of the effect of an intermediate cell stem cell exudate in epidermal repair in one of the embodiments of the present invention.
  • Placental mesenchymal stem cell secretion has a significant protective effect on skin fibroblasts.
  • CM placental mesenchymal stem cell secretory factor
  • CM placental mesenchymal stem cell secretory factor
  • the cosmetic effect of the placental stem cell secretory factor is achieved by the use of factors secreted by the placental mesenchymal stem cells to increase the amount of collagen produced and promote the growth of skin fibroblasts.
  • the reason why the skin is elastic is mainly because the collagen secreted by fibroblasts in the dermis of the skin forms a scaffold of the skin. This mixture increases the volume of collagen produced by the skin fibroblasts by several times, and the volume of the fibroblasts. The increase is also over 30%. So the constant generation of autologous collagen will make The thickness and density of the dermal layer of the skin is increased to fill wrinkles, eliminate scars, and restore skin elasticity and shine.
  • Placental mesenchymal stem cell secretions are usually added to cosmetic formulations. These secretions contain a variety of active ingredients, especially the cell growth factor group and the collagen group, which promote the synthesis of hydroxyproline and promote collagen. Collagenase synthesis, secretion of collagen, hyaluronic acid and glycoprotein, regulate collagen fibers, so it has the effect of moisturizing the skin, enhancing skin elasticity, reducing skin wrinkles and preventing skin aging.
  • MSC Mesenchymal stem cells
  • CM placental stem cell secretory factor
  • CM placental mesenchymal stem cell secretory factor
  • the ideal high-tech oral beauty product for repairing damaged skin and red bloodshot skin It is high in scientific content and is rich in various active factors such as basic fibroblast growth factor (FGF) and epidermal growth factor (EGF), and placental interstitial stem cells can secrete a large number of these growth factors.
  • FGF basic fibroblast growth factor
  • EGF epidermal growth factor
  • placental interstitial stem cells can secrete a large number of these growth factors.
  • FGF basic fibroblast growth factor
  • EGF epidermal growth factor
  • placental interstitial stem cells can secrete a large number of these growth factors.
  • These growth factors not only regulate Epidermal cells differentiate, proliferate and promote skin renewal, which also increases skin elasticity and restores skin moisture. It contains sedative repair components such as licorice, which repairs the stratum corneum.
  • the rich grape seed 0 PC is an effective component of antioxidant and anti-free radicals. It can repair cells, strengthen keratin repair, and protect the stratum corne

Description

分离动物胚胎间质性干细胞并提取其分泌物的方法
技术领域
[1] 本发明涉及细胞生物学领域, 更具体地说, 涉及一种分离动物胚胎间质性干细 胞并提取其分泌物的方法。
背景技术
Figure imgf000003_0001
cells , MSC) 是一类具有多分化潜能及自我更新能力的组织干细胞, 可以分化为 多种组织细胞: 成骨、 软骨、 脂肪、 神经细胞等。 其最早自骨髓中分离出来, 近年已有具有干 /祖细胞特征的间质性细胞自骨髓、 外周血、 密质骨、 软骨、 肌 肉等组织分离出来。 这些组织的共同特点是由来源于胚外中胚层的间充质和血 管共同构成。 间质性干细胞易于从骨髓中分离纯化, 进行有效的体外扩增, 具 有改善骨髓环境、 促进造血重建的作用。 在免疫特性方面, 间质性干细胞不表 达或仅表达可忽略水平的 MHCII类分子, 不相关供者的间质性干细胞不引起异体 淋巴细胞反应, 能下调异体免疫反应。 由于具有上述特性, MSC自发现后即迅 速成为细胞治疗、 基因治疗等方面的理想工程细胞, 以及组织工程尤其是骨或 软骨组织损伤修复中重要的种子细胞。
目前报道的间质性干细胞主要来源于骨髓, 釆用密度梯度分离法获得。 供者取 髓需要经历一个比较痛苦的手术, 而在取材过程中及取材后会有很高的感染几 率; 另外, 由于人体骨髓中间质性干细胞的含量极其稀少, 每 105~106个单个核 细胞中大约只有 1个间质性干细胞, 且随着年龄的增加, 或合并感染、 肿瘤等疾 病, 骨髓中间质性干细胞的数量以及增殖分化能力均显著下降, 使其在研究和 应用尤其是临床应用中受到很大限制。
[4] 附图 1示出了现有技术中分离间质性干细胞的常用方法, 包括以下步骤: (1) 胎盘从子宫娩出后立即放血, 得到样品; (2) 釆用持续灌注的方式, 或釆用胶 原酶消化法, 获得单细胞悬液; (3) 单细胞悬液经密度梯度离心法或免疫磁珠 分离法, 获得间质性干细胞。 该现有技术产出率较低, 无法快速得到大量的间 质性干细胞, 而且纯度较低; 此外, 处理过程对细胞的损伤程度较为严重, 难 以保证间质性干细胞的质量; 另外, 由于产出率较低, 也难以提取出具有良好 应用前景的分泌物。
[5] 因此需要一种新的分离动物胚胎间质性干细胞的方法, 能够迅速得到大量的、 高纯度且高质量的间质性干细胞, 还能实现其扩展应用。
发明内容
[6] 本发明的目的之一在于提供一种分离动物胚胎间质性干细胞并提取其分泌物的 方法, 旨在解决现有技术中存在的产出率、 纯度较低, 且难以保证细胞质量的 问题。
[7] 为了实现发明目的, 所述分离动物胚胎间质性干细胞的方法包括以下步骤:
[8] A.基于动物胎盘和 /或脐带取样, 对样品进行离心处理;
[9] B.利用酶类消化液对样品进行消化, 并制成单细胞悬液;
[10] C.在分离的单细胞中加入间质性干细胞 A型培养液, 进行细胞接种并培养; [11] D.对细胞进行贴壁纯化处理, 并通过磁珠分选得到间质性干细胞。
[12] 优选地, 所述步骤 A包括: A1.将胎盘内部组织块和 /或脐带中的血用含肝素的 生理盐水 (50单位肝素 /ml
生理盐水) 洗净, 剪碎得到样品; A2.将样品转入装有生理盐水的离心管中, 进 行离心处理。
[13] 优选地, 所述步骤 B中的酶类消化液包含混合胰酶 -EDTA (0.05%) 和 IV型胶 原酶, 按 1 : 1混合配制。
[14] 优选地, 所述步骤 B中的消化步骤包括: 将所述酶类消化液加入到离心管中, 在 37°C恒温水浴摇床中消化 1.5-2小吋。
[15] 优选地, 所述步骤 B中制成单细胞悬液的步骤包括: 在消化完毕后的溶液中加 入 3-5倍生理盐水稀释, 振荡均匀, 并用电动移液枪吸取过 ΙΟΟμηι细胞筛网, 从 而制成单细胞悬液。
[16] 优选地, 所述步骤 C包括: C1.单细胞悬液经 1600rpm、 lOmin离心后去上清; C
2.加入间质性干细胞 A型培养液, 摇匀并调整到 5-8xl04个细胞 /ml的细胞密度; C
3.将调整后的细胞溶液接种于 6孔板中, 置于 5%C02、 37°C、 饱和湿度的培养箱 中培养。
[17] 优选地, 所述步骤 D中的贴壁纯化处理包括: 用移液管将未贴壁的细胞吸出, 加入生理盐水清洗并换上新的间质性干细胞 A型培养液继续培养, 待贴壁细胞扩 增到培养瓶容积的 70%吋用胰酶 -EDTA (0.05%) 消化, 获得单细胞悬液。
[18] 优选地, 所述步骤 D中的磁珠分选包括: 釆用免疫磁珠分离法, 从所述单细胞 中筛选出 CD271和 CD73双阳性的细胞群, 即从胎盘分离出的间质性干细胞。
[19] 优选地, 所述步骤 D之后还包括: E.将所得的间质性干细胞进行增值和传代。
[20] 优选地, 所述步骤 D之后还包括: F.提取出间质性干细胞的分泌液。
[21] 优选地, 所述步骤 F包括: F1.利用酶类消化液对间质性干细胞进行消化处理; F2.在收集的细胞中加入培养基进行接种培养, 并加入间质性干细胞 B型培养液 促进细胞产生更多的分泌因子; F3.对收集到的培养液离心过滤, 得到分泌液。
[22] 优选地, 所述步骤 F1中的酶类消化液是指胰酶 -EDTA (0.05%) 。
[23] 为了实现发明目的, 所述提取间质性干细胞的分泌物的方法包括以下步骤: [24] Α'.利用酶类消化液对间质性干细胞进行消化处理;
[25] Β'.在收集的细胞中加入培养基进行接种培养, 并加入间质性干细胞 Β型培养液 促进细胞产生更多的的分泌因子;
[26] C.对收集到的培养液离心过滤, 得到分泌液。
[27] 优选地, 所述步骤 A'包括: A' l.利用胰酶 -EDTA (0.05%) 对间质性干细胞进 行消化处理; A,2.当所述间质性干细胞变圆脱落吋, 用含有牛血清的 1640培养液 终止消化。
[28] 优选地, 所述步骤 B'中加入培养基进行接种培养的步骤包括: 在收集的细胞中 加入间质性干细胞培养基, 摇匀并调整到 5-8xl04个细胞 /ml的细胞密度; 将调整 后的溶液接种到多个培养瓶中, 置于 5%C02、 37°C、 饱和湿度的培养箱中培养
[29] 优选地, 所述步骤 B'中加入间质性干细胞 B型培养液促进细胞产生更多的分泌 因子的步骤包括: 当培养瓶中的细胞层扩增至 80%吋, 吸出培养液并用磷酸盐缓 冲液清洗; 加入间质性干细胞 B型培养液, 刺激间质性干细胞产生更多的分泌因 子。 [30] 优选地, 所述步骤 C包括: 收集培养液, 经 2000rpm、 8min离心后收集上清液 ; 用 0.22u的过滤器过滤, 得到分泌液。
[31] 优选地, 其特征在于, 所述步骤 C之后还包括: D'.对所述分泌液进行浓缩。
[32] 优选地, 所述步骤 D'包括: D' l.将收获液加入超滤杯至工作体积, 完成装配; D'2.接入氮气进行过滤, 并收集过滤后的浓缩液。
[33] 由上可知, 本发明在分离间质性干细胞的过程中, 釆用 1 : 1混合的酶类消化液 包含混合胰酶 -EDTA (0.05%) 和 IV型胶原酶作为酶类消化液, 能够获得最多的 单细胞, 同吋将细胞受损程度降至最低; 另外通过贴壁纯化和免疫磁珠分离筛 选出的间质性干细胞, 提高了纯度; 此外, 在间质性干细胞培养的过程中加入 B 型干细胞培养液, 能刺激间质性干细胞产生更多的分泌因子, 因此, 从间质性 干细胞中提取出其分泌液含有更多的细胞分泌因子。
附图说明
[34] 图 1是现有技术中分离间质性干细胞的方法流程图;
[35] 图 2是本发明的一 4 、实施例中分离动物胚胎间质性干细胞的方法流程图;
[36] 图 3是本发明的一 4 、实施例中分离动物胚胎间质性干细胞的方法流程图;
[37] 图 4是本发明的一 4 、实施例中早期分离纯化的间质性干细胞的示意图;
[38] 图 5是本发明的一 4 、实施例中正在增殖的间质性干细胞的示意图;
[39] 图 6是本发明的一 4 、实施例中大量扩增的间质性干细胞的示意图;
[40] 图 7是本发明的一 4 、实施例中间质性干细胞表面蛋白表达鉴定的示意图;
[41] 图 8是本发明的一 4 、实施例中细胞化学方法诱导胎盘间质干细胞分化为脂肪、 软骨及成骨细胞的示意图;
[42] 图 9是本发明的一 4 、实施例中提取间质性干细胞的分泌物的方法流程图;
[43] 图 10是本发明的一个实施例中提取间质性干细胞的分泌物的方法流程图;
[44] 图 11是本发明的一个实施例中鉴定间质性干细胞的分泌因子的示意图;
[45] 图 12是本发明的一个实施例中经检测发现间质性干细胞的分泌物中含有大量 细胞生长因子群和胶原蛋白分子群;
图 13是本发明的一个实施例中间质性干细胞分泌液在表皮修复中的作用的示意 [47] 图 14是本发明的一个实施例中间质性干细胞分泌液在再生医学中的应用的示意 图。
[48] 为了使本发明的目的、 技术方案及优点更加清楚明白, 以下结合附图及实施例 , 对本发明进行进一步详细说明。 应当理解, 此处所描述的具体实施例仅仅用 以解释本发明, 并不用于限定本发明。
具体实施方式
[49] 本发明在分离间质性干细胞的过程中, 釆用 1 : 1混合的酶类消化液包含混合胰 酶 -EDTA (0.05%) 和 IV型胶原酶作为酶类消化液, 能够获得最多的单细胞, 同 吋将细胞受损程度降至最低; 另外通过贴壁纯化和免疫磁珠分离筛选出间质性 干细胞, 提高了纯度; 此外, 在间质性干细胞培养的过程中加入 B型干细胞培养 液, 能刺激间质性干细胞产生更多的分泌因子, 因此, 从间质性干细胞中提取 出其分泌液含有更多的细胞分泌因子。
[50] 图 2示出了本发明其中一个实施例中分离动物胚胎间质性干细胞的方法流程, 包括如下步骤: 在步骤 S201中, 基于动物胎盘和 /或脐带取样, 对样品进行离心 处理; 在步骤 S202中, 利用酶类消化液对样品进行消化, 并制成单细胞悬液; 在步骤 S203中, 在分离的单细胞中加入间质性干细胞 A型培养液, 进行细胞接种 并培养; 在步骤 S204中, 对细胞进行贴壁纯化处理, 并通过磁珠分选得到间质 性干细胞。
[51] 图 3示出了本发明其中一个实施例中分离动物胚胎间质性干细胞的方法流程, 包括如下步骤: 在步骤 S301中, 基于动物胎盘和 /或脐带取样, 对样品进行离心 处理。 具体过程与步骤 S201—致; 在步骤 S302中, 利用酶类消化液对样品进行 消化, 并制成单细胞悬液。 具体过程与步骤 S202—致; 在步骤 S303中, 通过单 细胞悬液得到分离的单细胞, 并在分离的单细胞中加入间质性干细胞 A型培养液 , 进行细胞接种并培养。 具体过程与步骤 S203—致; 在步骤 S304中, 对细胞进 行贴壁纯化处理, 并通过磁珠分选得到间质性干细胞。 具体过程与步骤 S204— 致; 在步骤 S305中, 将所得的间质性干细胞进行增值和传代。 此步骤相当于在 图 1基础上作出的一个扩展。
[52] 在一个实施例中, 上述步骤 S201和步骤 S301的具体实现过程是: [53] (1) 将动物胎盘内部组织块和 /或脐带中的血用含肝素的生理盐水洗净, 剪碎 得到样品。 需要说明的是, 本发明中所称的动物是一个广义概念, 包括高等动 物和低等动物, 因此所使用的胎盘可包括人胎盘以及牛、 马等动物的胎盘, 本 发明的保护范围并不限定于动物种类。
[54] 在一个优选实施例中, 对胎盘的处理方式是: 将新鲜的胎盘用剪刀去掉外面的 膜, 取内部暗红的组织块, 最好取血管密集部位的组织, 此处血管交织如树根 状, 用生理盐水 (加肝素, 500ml盐水加 2支肝素, 12500IU/支, 终浓度为: 50单 位肝素 /ml生理盐水) 洗净组织中的血液, 用不含肝素的生理盐水洗一遍, 然后 用剪刀将组织块剪碎 (越碎越好) 。 对脐带的处理方式是: 将脐带剪成约 2cm每 段, 用含肝素的盐水洗净血液, 纵向剪破, 洗净内部的血液, 再用不含肝素的 生理盐水洗一次, 用剪刀将脐带剪碎。 当然, 本发明并不限定于上述方式。
[55] (2) 将样品转入装有生理盐水的离心管中, 进行离心处理。
[56] 在一个优选实施例中, 将收集到的样品置入装有生理盐水的 50ml离心管中, 12 00rpm、 lOmin离心。
[57] 在一个实施例中, 上述步骤 S202和步骤 S302的具体实现过程是:
[58] (1) 离心后, 吸弃上清液, 按 1 : 1混合胰酶 -EDTA (0.05%) 和 IV型胶原酶, 加入 30ml到离心管中于 37°C恒温水浴摇床中消化 1.5-2h。
[59] 本发明釆用 1 : 1混合胰酶 -EDTA (0.05%) 和 IV型胶原酶作为酶类消化液来消 化胎盘, 消化吋间为 1.5-2h。 当然, 在消化处理的步骤中还可以釆用其他的配备 方案, 但是本发明釆用的配比方案和消化吋间 (1.5 - 2h) 能取得最佳效果; 经 反复实验表明, 用这种配备方案和消化吋间 (1.5 - 2h) , 能使酶对细胞的消化 损伤程度降至最低, 同吋又能获得最多的单细胞, 因此在消化过程中掌握好两 种酶的配置和消化吋间对成功的从人胎盘中分离间质干细胞至关重要。
[60] (2) 在消化完毕后的溶液中加入 3-5倍生理盐水稀释, 振荡均匀, 并用电动移 液枪吸取过 ΙΟΟμηι细胞筛网, 从而制成单细胞悬液。
[61] 在一个实施例中, 上述步骤 S203和步骤 S303的具体实现过程是: (1) 单细胞 悬液经 1600rpm、 lOmin离心后去上清。 (2) 加入间质性干细胞 A型培养液, 摇 匀并调整到 5-8xl04个细胞 /ml的细胞密度。 (3) 将调整后的溶液接种于 6孔板中 , 置于 5%C02、 37°C、 饱和湿度的培养箱中培养。
[62] 当然, 本发明还可釆取其他数据配置, 上述的实现方式并不用以限定本发明的 保护范围。
[63] 在一个实施例中, 上述步骤 S204和步骤 S304的具体实现过程是:
[64] (1) 贴壁纯化处理, 具体包括:
[65] 用移液管将未贴壁的细胞吸出, 加入生理盐水清洗并换上新的间质性干细胞 A 型培养液继续培养, 待贴壁细胞扩增到培养瓶容积的 70%吋用胰酶 -EDTA (0.05 ) 消化, 获得单细胞。
[66] 在本发明中, 通过 1 : 1混合胰酶 -EDTA (0.05%) 来消化后获得的单细胞悬液 通过普通离心 (1600r/min) 获得的单细胞, 在这种单细胞群体里面含有多种不 同生物学特性的细胞, 也混杂一些死细胞。 然后用培养间质性干细胞的培养液 进行筛选, 能存活并能贴壁生长的细胞大部分是间质性干细胞, 通过贴壁纯化 可以去掉大量非间质性干细胞,
[67] (2) 磁珠分选, 具体包括:
[68] 釆用免疫磁珠分离法, 从所述单细胞中筛选出 CD271和 CD73双阳性的细胞群 , 即从胎盘分离出的间质性干细胞。 磁珠分选可在最短吋间内获得大量活的、 高纯度的间质性干细胞
[69] 在一个实施例中, 上述步骤 S305的具体实现过程是: (1) 用移液枪吸去瓶内 的培养基。 (2) 加入少量磷酸盐缓冲液 (phosphate buffered
solution, PBS) 轻轻洗一遍, 吸弃, 从而平衡 PH值。 (3) 加入 0.05%胰酶 -EDT A, 酶液没过瓶底即可, 在显微镜下观察, 至大部分细胞变圆脱落即可用含有胎 牛血清的 1640培养液终止消化。 (4) 用移液枪吸取瓶内培养液反复吹打细胞层 , 收集细胞悬液至一个 50ml离心管, 再用 PBS洗培养瓶一次。 (5) 经 1200rpm、 8min离心细胞悬液, 去上清, 加入 PDMSC-A培养液, 打匀细胞, 按 1 : n的比例 进行传代扩瓶。 从而获得大量的胎盘间质性干细胞。 其中 η>1, 例如 n典型的可 取值为 4。
[70] 图 4示出了本发明其中一个实施例中早期分离纯化的间质性干细胞, 图 5是本发 明其中一个实施例中正在增殖的间质性干细胞, 图 6是本发明其中一个实施例中 大量扩增的间质性干细胞。
[71] 图 7是本发明其中一个实施例中间质性干细胞表面蛋白表达鉴定的示意图。 本 发明用流式细胞仪检测胎盘间质性干细胞表明细胞因子的表达, 可见分离培养 的胎盘间质干细胞表达 CD9、 CD29、 CD 105s CD166表面蛋白, 不表达 CD34、
CD13、 CD14、 CD45表面蛋白, 这群细胞生物特性稳定, 扩增一代和两代后的 细胞同质性分别达到 95%和 98%。
[72] 在该图中, 空心的浅色曲线是代表一种细胞因子表达的阴性对照, 实心黑颜色 图案表示细胞群体中表达相应细胞因子阳性率的高低。 如果实心黑颜色图案离 空心的浅色曲线越远, 这种细胞因子的阳性率就越高。
[73] 图 8是本发明其中一个实施例中细胞化学方法诱导胎盘间质干细胞分化为脂肪
、 软骨及成骨细胞的示意图。 胎盘间质干细胞 (PDMSC) 连续传代培养和冷冻 保存后仍能具有多向分化潜能, 而且保持正常的核型核端粒酶活性, 但不易自 发分化, 在体外特定的诱导条件下, PDMSC可以分化为骨、 软骨、 脂肪、 肌腱
、 肌肉、 神经等多种细胞。 其中:
[74] 图 A显示在加入成脂诱导剂后, 会导致胎盘间质干细胞分化为脂肪细胞且油红 染色为阳性, 浆内可见橙红色脂滴。 图 B显示加入成骨诱导剂后, 胎盘间质干细 胞分化为成骨细胞, Von Kossa进行成骨细胞鉴定。 Von
Kossa染色可见细胞深棕色,间布满黑色颗粒, 提示有矿化基质沉积。 图 C显示加 入软骨诱导剂对细胞进行诱导, 用阿尔新蓝染色显示有蛋白多糖表达。 图 D免疫 组化方法检测显示诱导分化后表达软骨细胞特有胶原蛋白 II—软骨细胞。
[75] 需要进行扩充说明的是, PDMSC作为人类胚胎干细胞 (hESC)和老鼠胚胎干细 胞 (mESC)滋养层的应用。 胎盘间质干细胞 (PDMSC) 作为细胞滋养层为人类胚 胎干细胞 (hESC)和老鼠胚胎干细胞 (mESC)提供生长支持, 并保持胚胎干细胞处 于未分化状态。 目前使用小鼠的胚胎纤维原细胞 (MEF)作为人类胚胎干细胞 (hES C)和老鼠胚胎干细胞 (mESQ的滋养层。 但是, 使用小鼠的胚胎纤维原细胞 (MEF )作为干细胞的生长滋养层受到诸多限制: 1.存在动物源性污染的风险; 2.提取大 量小鼠的胚胎纤维原细胞 (MEF)需要杀死许多小鼠。 使用健康人来源的胎盘间质 干细胞 (PDMSC) 作为胚胎干细胞的滋养层有独特的优势: 1.避免牺牲很多小 鼠, 取材于丢弃的健康人来源的胎盘组织; 2.避免了动物源性污染的风险; 3.使 用人体的胎盘间质干细胞 (PDMSC) 作为人体胚胎干细胞的滋养层对培养人体 胚胎干细胞更有利。
[76] 因此, 作为人类胚胎干细胞 (hESC)滋养层的来源, PDMSC是比小鼠的胚胎纤 维原细胞 (MEF)更理想的选择。
[77] 图 9是本发明其中一个实施例中提取间质性干细胞的分泌物的方法流程图。 在 步骤 S901中, 利用酶类消化液对间质性干细胞进行消化处理。 在步骤 S902中, 在收集的细胞中加入培养基进行接种培养, 并加入间质性干细胞 B型培养液促进 细胞产生更多的分泌因子。 在步骤 S903中, 对收集到的培养液离心过滤, 得到 分泌液。
[78] 图 10是本发明其中一个实施例中提取间质性干细胞的分泌物的方法流程图。 在 步骤 S1001中, 利用酶类消化液对间质性干细胞进行消化处理。 具体实现过程与 图 9中的步骤 S901—致。 在步骤 S1002中, 在分离的单细胞中加入培养基进行接 种培养, 并加入间质性干细胞 B型培养液促进细胞产生大量的分泌因子。 具体实 现过程与图 9中的步骤 S902—致。 在步骤 S1003中, 对收集到的培养液离心过滤 , 得到分泌液。 具体实现过程与图 9中的步骤 S903—致。 在步骤 S1004中, 对所 述分泌液进行浓缩。
[79] 在一个实施例中, 步骤 S901和步骤 S1001的具体执行过程包括:
[80] (1) 利用胰酶 -EDTA (0.05%) 对间质性干细胞进行消化处理。
[81] 在一个优选实施例中, 上述步骤的具体过程是: 细胞大量扩增后, 在 175cm2培 养瓶中长到 80%左右吋, 加入胰酶 -EDTA (0.05%) 。
[82] (2) 当所述间质性干细胞变圆脱落吋, 用含有牛血清的 1640培养液终止消化
[83] 在一个实施例中, 步骤 S902和步骤 S1002的具体执行过程包括:
[84] (1) 在收集的细胞中加入培养基进行接种培养。
[85] 在一个优选实施例中, 上述步骤的具体过程是: 在收集的细胞中加入间质性干 细胞培养基, 摇匀并调整到 5-8xl04个细胞 /ml的细胞密度; 将调整后的溶液接种 到培养瓶中, 置于 5%C02、 37°C、 饱和湿度的培养箱中培养。 [86] (2) 加入间质性干细胞 B型培养液促进细胞产生更多的分泌因子。
[87] 在一个优选实施例中, 上述步骤的具体过程是: 当培养瓶中的细胞层扩增至 80
%吋, 吸出培养液并用磷酸盐缓冲液清洗; 加入间质性干细胞 B型培养液, 刺激 间质性干细胞产生更多的分泌因子。
[88] 在一个实施例中, 步骤 S903和步骤 S1003的具体执行过程包括:
[89] (1) 收集培养液, 经 2000 rpm、 8min离心后收集上清液。
[90] 在一个优选实施例中, 上述步骤的具体过程是: 培养 3天后收集培养液。 经 200
0G、 8min离心收获液, 去除细胞碎片, 并收集上清液。
[91] (2) 用 0.22u的过滤器过滤, 得到分泌液。
[92] 在一个优选实施例中, 上述步骤的具体过程是: 用 0.22u的过滤器过滤, 过滤液 收集在 -20°C的条件下储存 2天, 然后放到 -80°C的条件下长期保存备用。
[93] 在一个实施例中, 步骤 S1004的具体执行过程包括:
[94] 在执行后述步骤之前, 需要准备超滤膜。 过程是: 先用 75%酒精冲洗超滤膜并 浸泡 lOmin; 用镊子夹住膜片边缘, 拿注射用水冲洗 3遍, 再放入干净容器盛装 的注射用水中浸泡过夜备用。
[95] (1) 将收获液加入超滤杯至工作体积, 完成装配。
[96] 在一个优选实施例中, 上述步骤的具体过程是: 按超滤杯说明书装好膜片、 杯 体、 搅拌系统, 加入收获液至工作体积, 再装上杯盖、 保护套。
[97] (2) 接入氮气进行过滤, 并收集过滤后的浓缩液。
[98] 在一个优选实施例中, 上述步骤的具体过程是: 接上氮气幵始过滤, 要注意的 是在过滤幵始吋应缓慢地加压, 有压力后再打幵磁力搅拌器; 过滤中氮气压力 不能超过 55PSI; 过滤结束后应缓慢降压。 最后, 当超滤杯中的收获液浓缩至 25 倍吋停止浓缩, 在超净台中收集浓缩液, 储存到 -80°C冰箱备用。
[99] 图 11是本发明其中一个实施例中鉴定间质性干细胞的分泌因子的示意图。 胎盘 间质干细胞分泌因子产物中含有大量的蛋白分子。 在胎盘间质干细胞培养增殖 过程中, 胎盘间质干细胞会分泌出许多生长因子、 蛋白质、 活性多肽等促进细 胞生长、 组织再生的物质。 在该附图中, 通过银染显示胎盘间质性干细胞分泌 的细胞因子与对照组有显著的差异, 胎盘间质性干细胞分泌物中含有大量的特 有的蛋白分子。
[100] 图 12是本发明其中一个实施例中经检测发现间质性干细胞的分泌物中含有大量 的细胞生长因子群和胶原蛋白分子群。 利用细胞活素抗体阵列对胎盘间质干细 胞分泌因子蛋白质组进行了测评。 发现了大量胎盘间质干性细胞分泌独特的基 因产物.这些基因产物中含有大量与细胞生长和代谢相关的生长因子群, 例如: B DNF、 EGF、 FGF、 FGF17、 FGF4、 FGF6、 FGF7、 FGF9、 GDNF、 HGF、 IGFB p、 PDGFBs PIGF、 TGFB1、 TGFb2、 TNFRSF11B、 VEGF、 IGF1和 LEP等; 以 及大量的胶原蛋白分子群, 例如: C0L11A1、 C0L12A1、 C0L16A1、 C0L1A、 C0L3A1、 C0L4A1、 COL5A和 COL6A等。 这些蛋白分子群对促进细胞的生长和 代谢具有重要的作用。
[101] 在该图中, 经检测发现胎盘间质性干细胞分泌物中含有大量的细胞生长因子群 和胶原蛋白分子群, 如图中箭头所指示。
[102] 在此需要说明间质性干细胞的各种分泌因子的功能, 主要阐述其在以下几个方 面的作用: 表皮修复、 人体美容、 再生医学、 保健品。
[103] 图 13是本发明其中一个实施例中间质性干细胞分泌液在表皮修复中的作用的示 意图。 胎盘间质干细胞分泌物对皮肤纤维幼细胞有显著的保护作用。 在对抗过 氧化氢的损伤和修复纤维幼细胞的试验中显示, 将培养液加入胎盘间质干细胞 分泌因子 (CM) 后能显著降低过氧化氢损伤导致的细胞死亡率
, 进而提高存活的纤维幼细胞的存活率。 在该附图中, 显示在对抗过氧化氢的 损伤和修复纤维幼细胞的试验中, 在培养液加入胎盘间质干细胞分泌因子 (CM ) 后能显著降低过氧化氢损伤导致的细胞死亡率, 而且随着 CM量的增加, 其纤 维幼细胞的存活率也明显增高。
[104] 关于分泌因子在人体美容方面的应用, 说明如下:
[105] 胎盘间质干细胞分泌因子的美容作用就是利用胎盘间质干细胞分泌的因子能够 增加胶原蛋白的生成量和促进皮肤纤维原细胞的生长来实现的。 皮肤之所以富 有弹性, 主要因为皮肤真皮层内成纤维细胞分泌的胶原蛋白形成了皮肤的支架 , 这种混合物使皮肤纤维原细胞制造的胶原蛋白的体积增加数倍, 同吋纤维原 细胞的体积增加也超过百分之三十。 所以源源不断产生自体胶原蛋白, 就会使 皮肤真皮层的厚度和密度增加, 填平皱纹、 消除疤痕、 恢复皮肤弹性和光泽。
[106] 通常将胎盘间质干细胞分泌物加到化妆品的配方中, 这些分泌物含有的多种活 性成份, 尤其是细胞生长因子群和胶原蛋白群, 可促进羟脯氨酸的合成, 促使 胶原及胶原酶合成, 分泌胶原物质、 透明质酸和糖蛋白, 调节胶原纤维, 故具 有滋润皮肤, 增强皮肤弹性, 减少皮肤皱纹和防止皮肤衰老的作用。
[107] 关于分泌因子在再生医学中的应用, 可参考图 14。
[108] 间质干细胞 (MSC) 已经在临床前和临床中用于治疗多种疾病。 人们认为它们 的作用机制有两种。 一是它们分化为功能正常的细胞, 用以取代损伤细胞; 二 是它们可以通过分泌旁分泌因子, 促进组织修复。
[109] 为了确定胎盘间质干细胞分泌因子 (CM) 是否真的参与间质干细胞对多种疾 病的治疗功能, 通过胎盘间质干细胞分泌因子 (CM) 注入心肌梗塞的小鼠体内 进行了测评。 把胎盘间质干细胞分泌因子注入心肌梗塞的小鼠体内, 结果显示 胎盘间质干细胞分泌因子对抗心肌缺血有显著的保护作用。
[110] 研究结果表明注射胎盘间质干细胞分泌因子 (CM) 不但显著降低心肌梗塞小 鼠的死亡率, 还能保护心脏功能 (左室射血分数, 核磁共震评估) , 以及减小 心肌梗塞面积。
[111] 关于分泌因子在保健品方面的应用, 说明如下:
[112] 目前修复受损皮肤及红血丝外露皮肤最理想的高科技口服美容品。 它科技含量 高, 富含各类活性因子, 如碱性纤维细胞生长因子 (FGF)和表皮生长因子 (EGF) , 而胎盘间质性干细胞能分泌大量的这些生长因子, 这些生长因子不仅能调节 表皮细胞的分化、 增殖和促进皮肤的更新, 还能增加皮肤的弹性、 恢复皮肤滋 润。 它蕴含甘草等镇静修复的成分, 对角质层进行修复, 此外, 丰富的葡萄籽 0 PC是抗氧化、 抗自由基的有效成分, 它能修复细胞, 强化角质修复, 还能保护 角质层, 避免角质层氧化发黄。 因此, 胎盘间质干细胞分泌因子在保健品中必 将发挥重要作用。
[113] 以上所述仅为本发明的较佳实施例而已, 并不用以限制本发明, 凡在本发明的 精神和原则之内所作的任何修改、 等同替换和改进等, 均应包含在本发明的保 护范围之内。

Claims

权利要求书
[1] 一种分离动物胚胎间质性干细胞的方法, 其特征在于, 所述方法包括以下 步骤:
A.基于动物胎盘和 /或脐带取样, 对样品进行离心处理;
B.利用酶类消化液对样品进行消化, 并制成单细胞悬液;
C.在分离的单细胞中加入间质性干细胞 A型培养液, 进行细胞接种并培养
D.对细胞进行贴壁纯化处理, 并通过磁珠分选得到间质性干细胞。
[2] 根据权利要求 1所述的分离动物胚胎间质性干细胞的方法, 其特征在于, 所 述步骤 A包括:
A1.将胎盘内部组织块和 /或脐带中的血用含肝素的生理盐水洗净, 剪碎得 到样品;
A2.将样品转入装有生理盐水的离心管中, 进行离心处理。
[3] 根据权利要求 1所述的分离动物胚胎间质性干细胞的方法, 其特征在于, 所 述步骤 B中的酶类消化液包含混合胰酶 -EDTA (0.05%) 和 IV型胶原酶, 按 1: 1混合配制。
[4] 根据权利要求 3所述的分离动物胚胎间质性干细胞的方法, 其特征在于, 所 述步骤 B中的消化步骤包括: 将所述酶类消化液加入到离心管中, 在 37°C 恒温水浴摇床中消化 1.5-2小吋。
[5] 根据权利要求 3所述的分离动物胚胎间质性干细胞的方法, 其特征在于, 所 述步骤 B中制成单细胞悬液的步骤包括: 在消化完毕后的溶液中加入 3-5倍 生理盐水稀释, 振荡均匀, 并用电动移液枪吸取过 ΙΟΟμηι细胞筛网, 从而 制成单细胞悬液。
[6] 根据权利要求 1所述的分离动物胚胎间质性干细胞的方法, 其特征在于, 所 述步骤 C包括:
C1.单细胞悬液经 1600rpm、 lOmin离心后去上清, 得到分离的单细胞;
C2.在分离的单细胞中加入间质性干细胞 A型培养液, 摇匀并调整到 5-8X104 个细胞 /ml的细胞密度; C3.将调整后的细胞溶液接种于 6孔板中, 置于 5%C02、 37°C、 饱和湿度的 培养箱中培养。
[7] 根据权利要求 1所述的分离动物胚胎间质性干细胞的方法, 其特征在于, 所 述步骤 D中的贴壁纯化处理包括: 用移液管将未贴壁的细胞吸出, 加入生 理盐水清洗并换上新的间质性干细胞 A型培养液继续培养, 待贴壁细胞扩 增到培养瓶容积的 70%吋用胰酶 -EDTA (0.05%) 消化, 获得单细胞悬液。
[8] 根据权利要求 7所述的分离动物胚胎间质性干细胞的方法, 其特征在于, 所 述步骤 D中的磁珠分选包括: 釆用免疫磁珠分离法, 从所述单细胞中筛选 出 CD271和 CD73双阳性的细胞群, 即从胎盘分离出的间质性干细胞。
[9] 根据权利要求 1至 8中任一项所述的分离动物胚胎间质性干细胞的方法, 其 特征在于, 所述步骤 D之后还包括:
E.将所得的间质性干细胞进行增值和传代。
[10] 根据权利要求 1至 8中任一项所述的分离动物胚胎间质性干细胞的方法, 其 特征在于, 所述步骤 D之后还包括:
F.提取出间质性干细胞的分泌液。
[11] 根据权利要求 10所述的分离动物胚胎间质性干细胞的方法, 其特征在于, 所述步骤 F包括:
F1.利用酶类消化液对间质性干细胞进行消化处理;
F2.在收集的细胞中加入培养基进行接种培养, 并加入间质性干细胞 B型培 养液促进细胞产生分泌因子;
F3.对收集到的培养液离心过滤, 得到分泌液。
[12] 根据权利要求 11所述的分离动物胚胎间质性干细胞的方法, 其特征在于, 所述步骤 F1中的酶类消化液是指胰酶 -EDTA (0.05%) 。
[13] —种提取间质性干细胞的分泌物的方法, 其特征在于, 所述方法包括以下 步骤:
Α'.利用酶类消化液对间质性干细胞进行消化处理;
Β'.在收集的单细胞中加入培养基进行接种培养, 并加入间质性干细胞 Β型 培养液促进细胞产生分泌因子; c.对收集到的培养液离心过滤, 得到分泌液。
[14] 根据权利要求 13所述的提取间质性干细胞的分泌物的方法, 其特征在于, 所述步骤 A'包括:
A' l.利用胰酶 -EDTA (0.05%) 对间质性干细胞进行消化处理; A,2.当间质性干细胞变圆脱落吋, 用含有牛血清的 1640培养液终止消化。
[15] 根据权利要求 13所述的提取间质性干细胞的分泌物的方法, 其特征在于, 所述步骤 B'中加入培养基进行接种培养的步骤包括:
在分离的单细胞中加入间质性干细胞培养基, 摇匀并调整到 5-8xl04个细胞 / ml的细胞密度;
将调整后的细胞溶液接种到多个培养瓶中, 置于 5%C02、 37°C、 饱和湿度 的培养箱中培养。
[16] 根据权利要求 15所述的提取间质性干细胞的分泌物的方法, 其特征在于, 所述步骤 B'中加入间质性干细胞 B型培养液促进细胞产生分泌因子的步骤 包括:
当培养瓶中的细胞层扩增至 80%吋, 吸出培养液并用磷酸盐缓冲液清洗; 加入间质性干细胞 B型培养液, 刺激间质性干细胞产生分泌因子。
[17] 根据权利要求 13所述的提取间质性干细胞的分泌物的方法, 其特征在于, 所述步骤 C包括:
收集培养液, 经 2000 rpm、 8min离心后收集上清液;
用 0.22u的过滤器过滤, 得到分泌液。
[18] 根据权利要求 13至 17中任一项所述的提取间质性干细胞的分泌物的方法, 其特征在于, 所述步骤 C之后还包括:
D'.对所述分泌液进行浓缩。
[19] 根据权利要求 18所述的提取间质性干细胞的分泌物的方法, 其特征在于, 所述步骤 D'包括:
D' 1.将收获液加入超滤杯至工作体积, 完成装配;
D'2.接入氮气进行过滤, 并收集过滤后的浓缩液。
PCT/CN2008/072648 2008-10-10 2008-10-10 分离动物胚胎间质性干细胞并提取其分泌物的方法 WO2010040262A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PCT/CN2008/072648 WO2010040262A1 (zh) 2008-10-10 2008-10-10 分离动物胚胎间质性干细胞并提取其分泌物的方法
CA2740092A CA2740092A1 (en) 2008-10-10 2009-09-18 Methods for isolating mesenchymal stem cells from embryo of human or animals and extracting secretion substances thereof
JP2010532419A JP2010538681A (ja) 2008-10-10 2009-09-18 人または動物胚から間葉系幹細胞を抽出及びその分泌物を抽出する方法
AU2009301517A AU2009301517A1 (en) 2008-10-10 2009-09-18 Methods for isolating mesenchymal stem cells from embryos of human or animals and extracting secretion substances thereof
CN200980000501A CN101802177A (zh) 2008-10-10 2009-09-18 从人或动物胚胎提取间质性干细胞及提取其分泌物的方法
PCT/CN2009/074031 WO2010040302A1 (zh) 2008-10-10 2009-09-18 从人或动物胚胎提取间质性干细胞及提取其分泌物的方法
KR1020107006511A KR20100065338A (ko) 2008-10-10 2009-09-18 인간 또는 동물 배아에서 중간엽 줄기세포를 추출 및 그 분비물을 추출하는 방법
EP09818766A EP2368974A1 (en) 2008-10-10 2009-09-18 Methods for isolating mesenchymal stem cells from embryos of human or animals and extracting secretion substances thereof
US12/678,745 US20110217385A1 (en) 2008-10-10 2009-09-18 Method for extracting mesenchymal stem cell from human or animal embryo and for extracting the secretion product thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2008/072648 WO2010040262A1 (zh) 2008-10-10 2008-10-10 分离动物胚胎间质性干细胞并提取其分泌物的方法

Publications (1)

Publication Number Publication Date
WO2010040262A1 true WO2010040262A1 (zh) 2010-04-15

Family

ID=42100191

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2008/072648 WO2010040262A1 (zh) 2008-10-10 2008-10-10 分离动物胚胎间质性干细胞并提取其分泌物的方法
PCT/CN2009/074031 WO2010040302A1 (zh) 2008-10-10 2009-09-18 从人或动物胚胎提取间质性干细胞及提取其分泌物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/074031 WO2010040302A1 (zh) 2008-10-10 2009-09-18 从人或动物胚胎提取间质性干细胞及提取其分泌物的方法

Country Status (8)

Country Link
US (1) US20110217385A1 (zh)
EP (1) EP2368974A1 (zh)
JP (1) JP2010538681A (zh)
KR (1) KR20100065338A (zh)
CN (1) CN101802177A (zh)
AU (1) AU2009301517A1 (zh)
CA (1) CA2740092A1 (zh)
WO (2) WO2010040262A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108815189A (zh) * 2018-09-27 2018-11-16 天津欣普赛尔生物医药科技有限公司 一种含有自体子宫内膜间充质干细胞外泌体的制剂
CN111565732A (zh) * 2018-01-12 2020-08-21 国立大学法人大阪大学 复层扁平上皮细胞的正常分化-成熟促进剂、上皮疾病治疗剂以及复层扁平上皮细胞的正常分化-成熟促进方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101583569B1 (ko) * 2013-05-15 2016-01-08 라정찬 정맥 투여용 줄기세포 조성물
JP5889856B2 (ja) * 2013-10-15 2016-03-22 佛教慈濟醫療財團法人 生体外でヒト間葉系幹細胞を増殖させる方法、およびそれに用いる補助剤、ならびに、生体外でヒト間葉系幹細胞の成長因子を取り出す方法およびその成長因子の用途
WO2015170347A2 (en) 2014-05-09 2015-11-12 Reelabs Private Limited Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders
CN108542877A (zh) * 2017-03-23 2018-09-18 广州资生生物科技有限公司 一种皮米级细胞提取物的制备方法
WO2018186421A1 (ja) * 2017-04-03 2018-10-11 株式会社カネカ 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN107142292B (zh) * 2017-06-21 2019-11-12 广州润虹医药科技股份有限公司 一种诱导多能干细胞分泌素的制备方法及其应用
CN110079459A (zh) * 2019-05-15 2019-08-02 刘宝全 一种干细胞培养容器内气体平衡的调节方法
CN110507597A (zh) * 2019-08-20 2019-11-29 苏州诺普再生医学有限公司 一种组合物及其制备方法、应用
CN111150746A (zh) * 2020-01-06 2020-05-15 湖南护宫福生物科技有限公司 一种用于阴道给药治疗妇科炎症的干细胞修复液
CN116179480A (zh) * 2020-03-31 2023-05-30 细胞外泌体治疗有限公司 增殖细胞和细胞生产物的生产法、间充质干细胞群和干细胞培养上清及其生产法、治疗剂
CN111643390A (zh) * 2020-07-16 2020-09-11 卡杜兰(广州)生命基因工程科技有限公司 一种将干细胞旁分泌因子浓缩、剔除无效杂质蛋白的制备方法
KR102435452B1 (ko) 2020-11-11 2022-09-07 이엔셀 주식회사 노화가 감소되고 줄기세포능이 보존된 초기 중간엽 줄기세포, 및 그 배양방법
CN116829125A (zh) * 2020-12-22 2023-09-29 株式会社韩诗珐玛 包含脐带来源间充质干细胞培养液作为活性成分的用于改善皮肤的组合物
CN113073077B (zh) * 2021-04-07 2023-03-17 德泉生物医学技术(深圳)有限公司 一种使用封闭式系统培养临床级脐带血间充质干细胞的方法
CN113321709A (zh) * 2021-05-18 2021-08-31 南方医科大学 自组装多肽、缓释外泌体多肽水凝胶及其制备方法和应用
CN113755445A (zh) * 2021-07-26 2021-12-07 蓝海细胞(北京)生物科技有限公司 一种用于皮肤修复的细胞外泌体的制备方法
WO2023143530A1 (zh) * 2022-01-28 2023-08-03 北京达尔文细胞生物科技有限公司 一种关节修复蛋白组合物及其制备方法和其应用
CN114717185A (zh) * 2022-03-31 2022-07-08 秦岭大熊猫研究中心(陕西省珍稀野生动物救护基地) 一种大熊猫胎盘间充质干细胞分离与培养方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1746297A (zh) * 2004-09-09 2006-03-15 中国人民解放军军事医学科学院基础医学研究所 胎盘来源间充质干细胞及其制备
WO2007079183A2 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Placental stem cell populations
CN101199550A (zh) * 2007-11-16 2008-06-18 中国医学科学院血液学研究所 利用脐带或胎盘制备含有内皮祖细胞制剂的方法及其用途
CN101270349A (zh) * 2008-03-20 2008-09-24 浙江大学 胎盘间充质干细胞分离和体外扩增培养方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004210713A (ja) * 2002-12-27 2004-07-29 Asahi Kasei Corp 医療用胎盤由来細胞製剤
CN1590537A (zh) * 2003-09-02 2005-03-09 中国人民解放军第四军医大学口腔医学院 外胚间充质干细胞的分离和培养方法
JP2009506770A (ja) * 2005-09-02 2009-02-19 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 前駆細胞株の誘導法
CN101374941A (zh) * 2005-12-29 2009-02-25 人类起源公司 采集和保存胎盘干细胞的改良组合物及其使用方法
CZ301148B6 (cs) * 2006-01-25 2009-11-18 Univerzita Karlova V Praze Zpusob pestování lidských mezenchymových kmenových bunek, zejména pro lécbu nehojících se fraktur, a bioreaktor k provádení tohoto zpusobu
CN104623642A (zh) * 2006-10-06 2015-05-20 人类起源公司 天然(端肽)胎盘胶原组合物
JP2010507392A (ja) * 2006-10-23 2010-03-11 アントフロゲネシス コーポレーション 胎盤細胞集団で骨欠損を治療するための方法及び組成物
CN101190174B (zh) * 2006-12-01 2011-01-26 高宝化妆品(中国)有限公司 一种保湿抗皱护肤霜及其制作方法
CA2629652A1 (en) * 2007-04-24 2008-10-24 Yaojiong Wu Compositions for preventing or treating skin defects and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1746297A (zh) * 2004-09-09 2006-03-15 中国人民解放军军事医学科学院基础医学研究所 胎盘来源间充质干细胞及其制备
WO2007079183A2 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Placental stem cell populations
CN101199550A (zh) * 2007-11-16 2008-06-18 中国医学科学院血液学研究所 利用脐带或胎盘制备含有内皮祖细胞制剂的方法及其用途
CN101270349A (zh) * 2008-03-20 2008-09-24 浙江大学 胎盘间充质干细胞分离和体外扩增培养方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FANG BAI-JUN ET AL.: "Preliminary study on the isolation and purification of umbilical cord-derived mesenchymal stem cells and their biological characteristics", PROCEEDING OF THE 10TH NATIONAL CONFERENCE ON EXPERIMENTAL HEMATOLOGY, 31 December 2005 (2005-12-31), pages 76 - 77 *
LU WEN-NING ET AL.: "Implantation of human placenta-derived mesenchymal stem cells improved cardiac function in rats with myocardial infarction", JOURNAL OF HARBIN MEDICAL UNIVERSITY, vol. 42, no. 3, 30 June 2008 (2008-06-30), pages 235 - 238,242 *
SHEN HUA: "Research advancement on human umbilical cord mesenchymal stem cells", CHINESE JOUMAL OF AESTHETIC MEDICINE, vol. 16, no. 8, 31 August 2007 (2007-08-31), pages 1158 - 1160 *
WU JIE-YING ET AL.: "Progress of study on placenta mesenchymal stem cells", J EXP HEMATOL, vol. 13, no. 3, 30 June 2005 (2005-06-30), pages 514 - 517 *
XIAOHONG ZHANG ET AL.: "Efficient adeno-associated virus-mediated gene expression in human placenta-derived mesenchymal cells", MICROBIOL. IMMUNOL., vol. 47, no. 1, 31 December 2003 (2003-12-31), pages 109 - 116 *
ZHANG HAO ET AL.: "Effect of human umbilical cord mesenchymal stem cell on mononuclear cell hematopoietic reconstruction in NOD/SCID mice", MED J CHIN PLA, vol. 33, no. 1, 31 January 2008 (2008-01-31), pages 39 - 41,51 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111565732A (zh) * 2018-01-12 2020-08-21 国立大学法人大阪大学 复层扁平上皮细胞的正常分化-成熟促进剂、上皮疾病治疗剂以及复层扁平上皮细胞的正常分化-成熟促进方法
CN108815189A (zh) * 2018-09-27 2018-11-16 天津欣普赛尔生物医药科技有限公司 一种含有自体子宫内膜间充质干细胞外泌体的制剂

Also Published As

Publication number Publication date
WO2010040302A1 (zh) 2010-04-15
AU2009301517A1 (en) 2010-04-15
JP2010538681A (ja) 2010-12-16
EP2368974A1 (en) 2011-09-28
US20110217385A1 (en) 2011-09-08
CA2740092A1 (en) 2010-04-15
CN101802177A (zh) 2010-08-11
KR20100065338A (ko) 2010-06-16

Similar Documents

Publication Publication Date Title
WO2010040262A1 (zh) 分离动物胚胎间质性干细胞并提取其分泌物的方法
CN110129265A (zh) 一种脐带间充质干细胞外泌体、制备方法及在化妆品中的应用
US11339372B2 (en) Serum-free medium inducing differentiation of umbilical cord mesenchymal stem cell into insulin-secretion-like cell and preparation method and use thereof
CN110540956B (zh) 由胎盘间充质干细胞简易制备细胞因子的方法
CN110269833A (zh) 一种脐带间充质干细胞制剂及其制备方法和应用
CN110898078B (zh) 一种间充质干细胞分泌因子的制备及应用
CN106967679B (zh) 一种高浓度葡萄糖溶液激活的间充质干细胞条件培养基的制备方法及其应用
CN110974944B (zh) 间充质干细胞复合活性因子冻干粉及其制备方法和应用
CN103898049B (zh) 一种活细胞精华液产品及其制备方法和应用
CN110812318B (zh) 用于化妆品原料的优化的成纤维细胞提取物的制备方法
CN110885786B (zh) 细胞因子在促进牙髓干细胞分泌外泌体中的应用
CN112111451B (zh) 提高干细胞细胞因子产量的方法
CN110129392A (zh) 一种脐带间充质干细胞因子的制备方法和用于制备干细胞精华液的用途
CN106038598A (zh) 人源干细胞分泌生物活性因子与裂解液的制备方法
CN111826348A (zh) 一种人诱导性多能干细胞来源的间充质干细胞体外高效制备方法和应用
CN113583952B (zh) 一种提高干细胞外泌体产量的培养液
CN112409456B (zh) 干细胞细胞因子在制备化妆品或药物中的用途
CN113197919A (zh) 鹿茸干细胞外泌体在制备改善或治疗骨关节炎和延缓细胞衰老的产品中的应用
CN115125192B (zh) 一种骨髓上清液及其在细胞培养中的应用
CN102119936B (zh) 制备利用人羊膜间充质细胞治疗缺血性脑损伤注射液的方法及其注射液
CN102703380A (zh) 亚全能干细胞、其制备方法及其用途
CN114874982A (zh) 一种增强脐带间充质干细胞分泌血管内皮生长因子的培养方法
TW201111502A (en) Method for extracting mesenchymal stem cell from embryo of animals and human, and method for extracting secretion from the extracting mesenchymal stem cell
CN111197028A (zh) 一种人体脂肪干细胞的培养方法
CN115025288B (zh) 一种外泌体水凝胶混合体系及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08877231

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, F1205A DATED 05-10-2011

122 Ep: pct application non-entry in european phase

Ref document number: 08877231

Country of ref document: EP

Kind code of ref document: A1